Shares of Obsidian Therapeutics (NASDAQ:OBX – Get Free Report) have been given an average rating of “Moderate Buy” by the six ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $42.50.
OBX has been the topic of several recent analyst reports. Piper Sandler initiated coverage on Obsidian Therapeutics in a research report on Wednesday, August 5th. They issued an “overweight” rating and a $42.00 price target on the stock. TD Cowen began coverage on shares of Obsidian Therapeutics in a research note on Thursday, August 6th. They issued a “buy” rating on the stock. William Blair started coverage on shares of Obsidian Therapeutics in a research report on Wednesday. They set an “outperform” rating on the stock. Weiss Ratings started coverage on shares of Obsidian Therapeutics in a research note on Wednesday, September 2nd. They set a “sell (d-)” rating for the company. Finally, Lifesci Capital initiated coverage on shares of Obsidian Therapeutics in a report on Tuesday, August 18th. They issued an “outperform” rating and a $43.00 price target for the company.
Read Our Latest Research Report on Obsidian Therapeutics
Obsidian Therapeutics Price Performance
Obsidian Therapeutics Company Profile
Obsidian Therapeutics is a biotechnology company focused on developing engineered cell and gene therapies for cancer and other serious diseases. The company’s approach is designed to improve the safety, control and effectiveness of therapeutic proteins and genetic medicines by enabling their activity to be regulated inside the body.
Obsidian’s technology platform, known as cytoDRiVE, uses small-molecule-controlled genetic systems to modulate the expression or activity of therapeutic proteins.
Recommended Stories
- Five stocks we like better than Obsidian Therapeutics
- Lululemon’s Problems May Not Be a Warning for Every Athleticwear Stock
- Roper Technologies In Rebound and a Hot Buy Despite Insider Selling
- PayPal’s Takeover Story Ended, But Its Turnaround Story Didn’t
- Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
Receive News & Ratings for Obsidian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obsidian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
